The problem of drug-resistant malaria.
D000655:Amodiaquine / Q000627:therapeutic use; D000852:Anopheles; D000962:Antimalarials / Q000627:therapeutic use*; D001208:Asia; D002738:Chloroquine / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D007303:Insect Vectors; D008288:Malaria / Q000188:drug therapy*; D009154:Mutation; D010963:Plasmodium falciparum / Q000254:growth & development; D011319:Primaquine / Q000627:therapeutic use; D002727:Proguanil / Q000627:therapeutic use; D011803:Quinine / Q000627:therapeutic use; D013020:South America; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D014774:Virulence
D000962:Antimalarials; D013449:Sulfonamides; D013450:Sulfones; D000655:Amodiaquine; D002738:Chloroquine; D011803:Quinine; D013752:Tetracycline; D011319:Primaquine; D002727:Proguanil